Lexicon Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Lexicon Pharmaceuticals hat ein Gesamteigenkapital von $288.9M und eine Gesamtverschuldung von $99.9M, was einen Verschuldungsgrad von 34.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $417.2M bzw. $128.4M.

Wichtige Informationen

34.6%

Verhältnis von Schulden zu Eigenkapital

US$99.87m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$355.60m
Eigenkapital	US$288.87m
Gesamtverbindlichkeiten	US$128.35m
Gesamtvermögen	US$417.22m

Jüngste Berichte zur Finanzlage

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Apr 25

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Jan 04

Recent updates

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Apr 25

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Jan 04

Lexicon Pharma: Key Regulatory Event In May 2023

Oct 01

Lexicon announces FDA review of heart failure therapy

Jul 27

Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win

Jul 13

Lexicon Pharmaceuticals up 9% on mid-stage study for diabetic neuropathy drug

Jun 29

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: LXRXDie kurzfristigen Aktiva des Unternehmens ($364.6M) übersteigen seine kurzfristigen Passiva ($23.4M).

Langfristige Verbindlichkeiten: LXRXDie kurzfristigen Vermögenswerte des Unternehmens ($364.6M) übersteigen seine langfristigen Verbindlichkeiten ($105.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: LXRX über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: LXRX hatte vor 5 Jahren ein negatives Eigenkapital, ist jetzt aber positiv und hat sich somit verbessert.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: LXRX auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: LXRX verfügt über eine ausreichende Liquiditätsreserve für 1.4 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 9.9% pro Jahr abnimmt.

Lexicon Pharmaceuticals Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Recent updates

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $62.795767 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $62.204233 million.

Lexicon Pharmaceuticals, Inc. Announces Fda Approval of Inpefa™ (Sotagliflozin) for Treatment of Heart Failure

Consensus revenue estimates increase by 31%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Consensus EPS estimates fall by 13%

Full year 2022 earnings: EPS and revenues miss analyst expectations

CEO & Director exercised options and sold US$111k worth of stock

Does Lexicon Pharmaceuticals (NASDAQ:LXRX) Have A Healthy Balance Sheet?

Lexicon Pharmaceuticals, Inc. Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

Price target decreased to US$8.00

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. Announces New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

Lexicon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Lexicon Phmaceuticals, Inc. Announces That New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events

Lexicon Pharma: Key Regulatory Event In May 2023

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Lexicon Pharmaceuticals, Inc. Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure

Lexicon announces FDA review of heart failure therapy

Lexicon Pharmaceuticals: Encouraging Signs Of Efficacy In Pain, But Still Looking For A Clear Win

Price target increased to US$12.50

Lexicon Pharmaceuticals, Inc. Announces Positive Top-Line Results from Phase 2 Proof-Of-Concept Study of Lx9211 in Painful Diabetic Neuropathy

Lexicon Pharmaceuticals up 9% on mid-stage study for diabetic neuropathy drug

Analyse der Finanzlage